Antonio Passaro

机构：Twitter (United States), European Institute of Oncology · ORCID：0000-0002-7575-3870

发表论文 214 篇 · 总被引 9946 次 · h-index 44

代表论文

• Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 113)
• ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0) (2025 · Annals of Oncology · 被引 56)
• Patritumab deruxtecan (HER3-DXd) in resistant EGFR -mutated ( EGFR m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study. (2025 · Journal of Clinical Oncology · 被引 43)
• HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs—A Long Way to the Top (2025 · Molecules · 被引 20)
• Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States (2025 · Journal of Thoracic Oncology · 被引 20)
• Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab (2025 · Journal of Clinical Oncology · 被引 15)